ArticleImmunity, inflammation and disease2022
Identification of B-cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus.
Article in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- miR-378a-5p targeting BRAF regulates CD4Frontiers in immunology · 2025Article
- Optimizing sheep B-cell epitopes inFrontiers in immunology · 2024Article
- Immunogenicity of peptide-based vaccine composed of epitopes from Echinococcus granulosus rEg.P29.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Recombinant antigen P29 ofFrontiers in immunology · 2023Article
- Identification of B-cell dominant epitopes in the recombinant protein P29 from Echinococcus granulosus.Immunity, inflammation and disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEchinococcus granulosus (E. granulosus) causes a hazardous zoonotic parasitic disease. This parasite can occupy the liver and several areas of the body, causing incurable damage. Our previous studies have provided evidence that the recombinant protein P29 (rEg.P29) exhibit immune protection in sheep and mice against pathological damage induced by E. granulosus, showing its potential as candidate for vaccine development. However, information on the B-cell epitopes of rEg.P29 has not yet been reported.
methodsImmunological model was established in mice with rEg.P29. SDS-PAGE and Western blot were used to identify protein. Screening for B-cell dominant epitope peptides of rEg.P29 by enzyme-linked immunosorbent assay (ELISA) and immune serum. Dominant epitopes were validated using ELISA and flow cytometry. Multiple sequence alignment analysis was performed using BLAST and UniProt.
resultsImmunization with rEg.P29 induced intense and persistent antibody responses, and the epitope of the dominant antigen of B cells are identified as rEg.P29
conclusionrEg.P29
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.